Previous Close | 1.4000 |
Open | 1.4200 |
Bid | 0.0000 x 1100 |
Ask | 0.0000 x 1000 |
Day's Range | 1.4001 - 1.5000 |
52 Week Range | 1.0500 - 29.2500 |
Volume | |
Avg. Volume | 175,986 |
Market Cap | 10.832M |
Beta (5Y Monthly) | 0.18 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.3350 |
Earnings Date | Feb 15, 2023 - Feb 20, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 1.50 |
Subscribe to Yahoo Finance Plus to view Fair Value for TTOO
LEXINGTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it has advanced to the Phase 2 accelerator in the U.S. Department of Health and Human Services (“HHS”) and the Steven & Alexandra Cohen Foundation’s (“Cohen Foundation”) LymeX Diagnostics Prize. The goal of the multiphase LymeX Innovation Accelerator (LymeX) prize competition is to nurture the devel
LEXINGTON, Mass., Feb. 03, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, and antibiotic resistance genes, announced today that it issued inducement awards to fourteen new employees. The awards were made on January 30, 2023, under the T2 Biosystems’ Inducement Award Plan (the "Inducement Plan"), which was adopted on March 1, 2018 and amended and restated on December 17, 2021 and provides for the granting of equity awards to
Achieved record sepsis product revenue and sepsis-driven T2Dx Instrument units in 2022LEXINGTON, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results for the fourth quarter and full year 2022. Full Year 2022 and Recent Highlights (unaudited) Achieved full year 2022 total revenue of $22.3 million, including prod